US 12,291,730 B2
Serine protease variants and polynucleotides encoding same
Keiichi Ayabe, Konakadaicho (JP); Tomoko Matsui, Chiba (JP); Aki Tomiki, Chiba (JP); Yuma Kurakata, Chiba (JP); Esben Peter Friis, Herlev (DK); Jens Erik Nielsen, Bagsværd (DK); and Roland Alexander Pache, Valby (DE)
Assigned to Novozymes A/S, Bagsvaerd (DK)
Filed by Novozymes A/S, Bagsvaerd (DK)
Filed on Dec. 9, 2021, as Appl. No. 17/547,098.
Application 17/547,098 is a division of application No. 17/148,790, filed on Jan. 14, 2021, granted, now 11,447,763.
Application 17/148,790 is a division of application No. 16/318,496, granted, now 10,927,361, issued on Feb. 23, 2021, previously published as PCT/EP2017/067883, filed on Jul. 14, 2017.
Claims priority of application No. 16180497 (EP), filed on Jul. 21, 2016; and application No. 16195078 (EP), filed on Oct. 21, 2016.
Prior Publication US 2022/0090041 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/58 (2006.01); C12P 7/06 (2006.01)
CPC C12N 9/58 (2013.01) [C12P 7/06 (2013.01); C12Y 304/21 (2013.01)] 25 Claims
 
1. A protease variant comprising a modification at one or more positions corresponding to positions 39, 50, 57, 60, 74, 81, 84, 109, 110, 111, 115, 117, 124, 128, 145, 146, 154, 182, 187, 207, 209, 210, 212, 228, 267, 271, 272, 274, 278, 280, 294, 317, 318, 320, 321, 322, 328, 343, 348, 362 or 363 of the polypeptide of SEQ ID NO: 3, wherein the variant has
(a) protease activity,
(b) at least 90%, but less than 100% sequence identity to the mature polypeptide of SEQ ID NO: 3, and
(c) increased thermostability compared to the protease of SEQ ID NO: 3.